CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues
Revenues	$ 1,944	$ 1,918
Expenses
Selling, general and administrative	725	622
Research and development	143	127
Amortization of intangible assets	273	310
Asset impairments	13	8
Restructuring, integration, separation and IPO costs	10	13
Other expense, net	23	2
Total expenses	1,769	1,633
Operating income	175	285
Interest income	6	2
Interest expense	(307)	(362)
Foreign exchange and other	(10)	(7)
Loss before income taxes	(136)	(82)
(Provision for) benefit from income taxes	(73)	16
Net loss	(209)	(66)
Net loss (income) attributable to noncontrolling interest	8	(3)
Net loss attributable to Bausch Health Companies Inc.	$ (201)	$ (69)
Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.55)	$ (0.19)
Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.55)	$ (0.19)
Basic weighted-average common shares (in shares)	363.3	360.8
Diluted weighted-average common shares (in shares)	363.3	360.8
Product sales
Revenues
Revenues	$ 1,922	$ 1,891
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	572	536
Other revenues
Revenues
Revenues	22	27
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 10	$ 15